Research ArticleSupplement
Proceedings of the 2019 Canadian Inflammatory Myopathy Study Symposium: Clinical Trial Readiness in Myositis
Valérie Leclair, Océane Landon-Cardinal, Rohit Aggarwal, Nick Bansback, Craig Campbell, Brian M. Feldman, Martin Jarry, Suzan McNamara, Barbara White and Marie Hudson for the CIMS Investigators
The Journal of Rheumatology June 2020, jrheum.200480; DOI: https://doi.org/10.3899/jrheum.200480
Valérie Leclair
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Océane Landon-Cardinal
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Rohit Aggarwal
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Nick Bansback
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Craig Campbell
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Brian M. Feldman
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Martin Jarry
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Suzan McNamara
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Barbara White
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Marie Hudson
From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada. As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer. V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute. Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Article Information
jrheum.200480
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 15, 2020.
Article Versions
- You are currently viewing a Latest version of this article (June 15, 2020 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2020 The Journal of Rheumatology
Author Information
- Valérie Leclair,
- Océane Landon-Cardinal,
- Rohit Aggarwal,
- Nick Bansback,
- Craig Campbell,
- Brian M. Feldman,
- Martin Jarry,
- Suzan McNamara,
- Barbara White and
- Marie Hudson; for the CIMS Investigators
- From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Québec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada.
As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.
This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology cAre (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer.
V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and IHPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute.
Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, A.725-3755 Chemin de la Côte-Sainte- Catherine,
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Proceedings of the 2019 Canadian Inflammatory Myopathy Study Symposium: Clinical Trial Readiness in Myositis
Valérie Leclair, Océane Landon-Cardinal, Rohit Aggarwal, Nick Bansback, Craig Campbell, Brian M. Feldman, Martin Jarry, Suzan McNamara, Barbara White, Marie Hudson
The Journal of Rheumatology Jun 2020, jrheum.200480; DOI: 10.3899/jrheum.200480
Proceedings of the 2019 Canadian Inflammatory Myopathy Study Symposium: Clinical Trial Readiness in Myositis
Valérie Leclair, Océane Landon-Cardinal, Rohit Aggarwal, Nick Bansback, Craig Campbell, Brian M. Feldman, Martin Jarry, Suzan McNamara, Barbara White, Marie Hudson
The Journal of Rheumatology Jun 2020, jrheum.200480; DOI: 10.3899/jrheum.200480